Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Tovorafenib in Relapsed/Refractory Langerhans Cell Histiocytosis
NCT05828069Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2024
- Primary completion
- Sep 2028
- Countries
- 3
01
Overview
A Phase 2 trial of tovorafenib in Langerhans cell histiocytosis (LCH), sponsored by National Cancer Institute. Started Mar 2024; status: recruiting.
02
Drugs
tovorafenib
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on NCT05828069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05828069.